In summary, KIF22 expression levels are negatively correlated with pancreatic cancer clinical prognosis, and it participates in cell cycle regulation via MEK/ERK/P21, promotes the occurrence and development of pancreatic cancer, can be used as a prognostic factor for pancreatic cancer patients, and may be a potential target for pancreatic cancer adjuvant therapy. Here, KIF22 is linked to familial pancreatic carcinoma.